CDH1 and lip and oral cavity carcinoma: Although some studies have explored the immunoreactivity of E-cadherin in potentially malignant disorders, non-tumor epithelium adjacent to oral cancer and oral squamous cell carcinoma, it remains unclear if E-cadherin could be used as biomarker to predict malignant transformation [10, 22, 23].